Journal of Clinical Oncology, Vol 3, 1174-1182, Copyright © 1985 by American Society of Clinical Oncology

ARTICLES

MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

P Klimo and JM Connors

Seventy patients with advanced Hodgkin's disease, 54 with new disease, and 16 in first relapse after initial radiotherapy, have been treated with a seven-drug, 8-month program: MOPP (nitrogen mustard, vincristine, procarbazine, prednisone)/ABV (Adriamycin [Adria Laboratories of Canada, Mississauga, Ontario], bleomycin, vinblastine) hybrid. A single involved field of radiotherapy was given to selected partial responders after 6 months of chemotherapy. Forty-six of the 52 (88%) evaluable new-disease patients and 14 of the 16 (87%) evaluable patients with relapsing disease reached a complete response. The actuarial overall survival at 49 months for the patients with new disease was 90% (median follow-up from diagnosis was 27 months). For the patients with relapsing disease, the actuarial survival at 54 months was 79% (median follow-up from diagnosis was 27 months). The actuarial relapse-free survival at 41 months for complete responders was 93% for patients with new disease (median follow-up after treatment was 20 months) and 80% for those with relapsing disease (median follow- up after treatment was 27 months). Toxicity was moderate, with two treatment-related deaths and eight episodes of serious infection. These results compare favorably with the best results reported in the literature. Furthermore, they were achieved with a moderate level of toxicity, high drug delivery rates, and a relatively short duration of treatment. The efficacy and toxicity data of the MOPP/ABV hybrid program will now be evaluated in a prospectively randomized multicenter study.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dorken, W.-D. Ludwig, P. Koch, M. Hanel, M. Pfreundschuh, M. Wilhelm, et al. Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study J. Clin. Oncol., September 20, 2009; 27(27): 4548 - 4554. [Abstract] [Full Text] [PDF]

				F. Morschhauser, P. Brice, C. Ferme, M. Divine, G. Salles, R. Bouabdallah, C. Sebban, L. Voillat, O. Casasnovas, A. Stamatoullas, et al. Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group J. Clin. Oncol., December 20, 2008; 26(36): 5980 - 5987. [Abstract] [Full Text] [PDF]

				M. A.E. van der Kaaij, N. Heutte, N. Le Stang, J. M.M. Raemaekers, A. H.M. Simons, P. Carde, E. M. Noordijk, C. Ferme, J. Thomas, H. Eghbali, et al. Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., July 1, 2007; 25(19): 2825 - 2832. [Abstract] [Full Text] [PDF]

				L. M.L. Chow, P. C. Nathan, D. C. Hodgson, D. Jenkin, S. Weitzman, R. M. Grant, D. Manson, A. Bross, J. J. Doyle, C. Danjoux, et al. Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation J. Clin. Oncol., December 20, 2006; 24(36): 5735 - 5741. [Abstract] [Full Text] [PDF]

				E. M. Noordijk, P. Carde, N. Dupouy, A. Hagenbeek, A. D.G. Krol, J. C. Kluin-Nelemans, U. Tirelli, M. Monconduit, J. Thomas, H. Eghbali, et al. Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials J. Clin. Oncol., July 1, 2006; 24(19): 3128 - 3135. [Abstract] [Full Text] [PDF]

				B. D. Cheson and G. P. Canellos The cancer and leukemia group B lymphoma committee. Clin. Cancer Res., June 1, 2006; 12(11): 3572s - 3575s. [Abstract] [Full Text] [PDF]

				P. W.M. Johnson, J. A. Radford, M. H. Cullen, M. R. Sydes, J. Walewski, A. S. Jack, K. A. MacLennan, S. P. Stenning, S. Clawson, P. Smith, et al. Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519) J. Clin. Oncol., December 20, 2005; 23(36): 9208 - 9218. [Abstract] [Full Text] [PDF]

				M. Sieber, H. Tesch, B. Pfistner, U. Rueffer, U. Paulus, R. Munker, R. Hermann, G. Doelken, P. Koch, J. Oertel, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial Ann. Onc., February 1, 2004; 15(2): 276 - 282. [Abstract] [Full Text] [PDF]

				M. Federico, M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. Colombat, S. Luminari, F. Fabbiano, et al. High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2320 - 2325. [Abstract] [Full Text] [PDF]

				B. M.P. Aleman, J. M.M. Raemaekers, U. Tirelli, R. Bortolus, M. B. van 't Veer, M. L.M. Lybeert, J. J. Keuning, P. Carde, T. Girinsky, R. W.M. van der Maazen, et al. Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma N. Engl. J. Med., June 12, 2003; 348(24): 2396 - 2406. [Abstract] [Full Text] [PDF]

				D. B. Duggan, G. R. Petroni, J. L. Johnson, J. H. Glick, R. I. Fisher, J. M. Connors, G. P. Canellos, and B. A. Peterson Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial J. Clin. Oncol., February 15, 2003; 21(4): 607 - 614. [Abstract] [Full Text] [PDF]

				J. A. Radford, A. Z.S. Rohatiner, W. D.J. Ryder, D. P. Deakin, T. Barbui, N. P. Lucie, A. Rossi, D. J. Dunlop, R. A. Cowan, P. M. Wilkinson, et al. ChlVPP/EVA Hybrid Versus the Weekly VAPEC-B Regimen for Previously Untreated Hodgkin's Disease J. Clin. Oncol., July 1, 2002; 20(13): 2988 - 2994. [Abstract] [Full Text] [PDF]

				C. Ferme, N. Mounier, M. Divine, P. Brice, A. Stamatoullas, O. Reman, L. Voillat, J. Jaubert, P. Lederlin, P. Colin, et al. Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial J. Clin. Oncol., January 15, 2002; 20(2): 467 - 475. [Abstract] [Full Text] [PDF]

				M. Sieber, H. Tesch, B. Pfistner, U. Rueffer, B. Lathan, O. Brosteanu, U. Paulus, T. Koch, M. Pfreundschuh, M. Loeffler, et al. Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5 J. Clin. Oncol., January 15, 2002; 20(2): 476 - 484. [Abstract] [Full Text] [PDF]

				C. Thieblemont, A. Mayer, C. Dumontet, Y. Barbier, E. Callet-Bauchu, P. Felman, F. Berger, X. Ducottet, C. Martin, G. Salles, et al. Primary Thyroid Lymphoma Is a Heterogeneous Disease J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 105 - 111. [Abstract] [Full Text] [PDF]

				P. C. Bishop, W. H. Wilson, D. Pearson, J. Janik, E. S. Jaffe, and P. C. Elwood CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma J. Clin. Oncol., August 1, 1999; 17(8): 2479 - 2479. [Abstract] [Full Text] [PDF]

				A. R. Yuen, S. A. Rosenberg, R. T. Hoppe, J. D. Halpern, and S. J. Horning Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's Disease Blood, February 1, 1997; 89(3): 814 - 822. [Abstract] [Full Text] [PDF]

				V. T. DeVita and S. M. Hubbard Hodgkin's Disease N. Engl. J. Med., February 25, 1993; 328(8): 560 - 565. [Full Text]

				R. Donhuijsen-Ant, H. Abken, G. Bornkamm, K. Donhuijsen, H. Grosse-Wilde, D. Neumann-Haefelin, M. Westerhausen, and H. Wiegand Fatal Hodgkin and Non-Hodgkin Lymphoma Associated with Persistent Epstein-Barr Virus in Four Brothers Ann Intern Med, December 15, 1988; 109(12): 946 - 952. [Abstract] [PDF]

				G. BONADONNA, P. VALAGUSSA, and A. SANTORO Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's Disease: A Report of 8-Year Results Ann Intern Med, June 1, 1986; 104(6): 739 - 746. [Abstract] [PDF]

				J. H. GLICK and A. TSIATIS MOPP/ABVD Chemotherapy for Advanced Hodgkin's Disease Ann Intern Med, June 1, 1986; 104(6): 876 - 878. [Abstract] [PDF]